Pharmacy | Home | MIMS Malaysia

Malaysia
Search
Sign In

Pharmacy

Pharmacy

Home News Conferences Special Reports Multimedia

Acid-suppressing drugs potentially chemopreventive in Barret’s oesophagus

Jairia Dela Cruz, an hour ago

Use of proton pump inhibitors and histamine‐2 receptor antagonists appears to reduce the risk of developing oesophageal carcinoma in patients with Barret’s oesophagus, according to a study.

Sodium thiosulfate may prevent cisplatin-induced hearing loss

Roshini Claire Anthony, 21 hours ago

Administering sodium thiosulfate 6 hours after cisplatin therapy almost halved the incidence of hearing loss in children with hepatoblastoma, according to results of the phase III SIOPEL 6* trial.

Elobixibat provides relief for chronic constipation

Pearl Toh, Yesterday

The novel local-acting ileal bile acid transporter inhibitor elobixibat helps relieve chronic constipation in the short term, with well tolerated safety profile in the long term — supporting the novel approach of increasing intracolonic bile acid concentration for treating chronic constipation, two phase III studies show.

Canakinumab controls, prevents flares in autoinflammatory recurrent fever syndromes

Yesterday

Canakinumab provides effective flare control and prevention in patients with monogenic autoinflammatory diseases, namely colchicine-resistant familial Mediterranean fever, mevalonate kinase deficiency and tumour necrosis factor receptor–associated periodic syndrome, according to the results of a phase III CLUSTER trial.

Zoledronic acid may prevent bone loss associated with cancer treatment

Jairia Dela Cruz, 2 days ago

Use of zoledronic acid for 2 years appears to be effective against cancer treatment-induced bone loss in premenopausal women with breast cancer, with bone mass density values maintained for up to 3 years after cessation of treatment, according to the results of the placebo-controlled ProBone II trial.

Meta-analysis: Infliximab, adalimumab ranked highest for clinical remission induction in CD

2 days ago

Infliximab or adalimumab may be preferred for first-line therapy and ustekinumab for second‐line therapy in patients with moderate-to-severe Crohn’s disease (CD), according to a study.

Improving Medical Practice through Advancement in Clinical Treatment: IMPACT Aesthetics & Suturing Workshop 2018

Dr. Steven Ang, Dr. Leo Kah Woon, 11 Jul 2018

DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.

Excerpts from Journey to Pain-Free Living Starts with You – CPD workshop for pharmacists

01 Mar 2018

Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.

Dual-hormone artificial pancreas beats insulin-alone system in glycaemic control in small study

Pearl Toh, 10 Jul 2018

A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.

Sotagliflozin sustains HbA1c reductions, improves outcomes over 1 year in T1D

Roshini Claire Anthony, 10 Jul 2018

Combining the dual sodium glucose cotransporter (SGLT) 1 and 2 inhibitor sotagliflozin with optimized insulin therapy led to sustained reductions in HbA_1c levels over 1 year in adults with type 1 diabetes (T1D), according to a study presented at ADA 2018.

Exenatide-dapagliflozin efficacy for T2D persists for 2 years

Elvira Manzano, 06 Jul 2018

Combined treatment with the GLP-1 receptor agonist exenatide and the SGLT-2 inhibitor dapagliflozin appeared to be effective up to 2 years in patients with type 2 diabetes (T2D), the phase III DURATION-8 extension trial has shown.

No increased risk of below-knee amputation with canagliflozin

Roshini Claire Anthony, 05 Jul 2018

The sodium glucose co-transporter 2 (SGLT-2) inhibitor canagliflozin does not appear to increase the risk of below-knee lower extremity amputations over other SGLT2 inhibitors or non-SGLT2 inhibitor antihyperglycaemic agents in patients with type 2 diabetes (T2D), but may reduce the risk of hospitalization for heart failure (HHF), according to findings of the US-based OBSERVE-4D* study.

Intensified multifactorial treatment highly cost-effective for high-risk T2D patients

Stephen Padilla, 05 Jul 2018

Intensified multipronged treatment in patients with type 2 diabetes (T2D) for 7.8 years is not associated with any significant increase in total costs or in costs per person-year when compared to conventional multipronged treatment over a follow-up of 21.2 years, according to the results of the Steno 2 Study presented at the 78th Scientific Sessions of the American Diabetes Association (ADA 2018).

Ertugliflozin improves glycaemic outcomes in T2D

Audrey Abella, 05 Jul 2018

The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!